- Home
- EXEL vs CHRW Comparison
EXEL vs CHRW Comparison
Compare EXEL & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- CHRW
- Stock Information
- Founded
- EXEL 1994
- CHRW 1905
- Country
- EXEL United States
- CHRW United States
- Employees
- EXEL 1147
- CHRW N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- CHRW Oil Refining/Marketing
- Sector
- EXEL Health Care
- CHRW Consumer Discretionary
- Exchange
- EXEL Nasdaq
- CHRW Nasdaq
- Market Cap
- EXEL 11.3B
- CHRW 10.7B
- IPO Year
- EXEL 2000
- CHRW 1997
- Fundamental
- Price
- EXEL $40.37
- CHRW $92.63
- Analyst Decision
- EXEL Buy
- CHRW Buy
- Analyst Count
- EXEL 18
- CHRW 19
- Target Price
- EXEL $39.59
- CHRW $113.00
- AVG Volume (30 Days)
- EXEL 2.6M
- CHRW 1.0M
- Earning Date
- EXEL 08-05-2025
- CHRW 07-30-2025
- Dividend Yield
- EXEL N/A
- CHRW 2.65%
- EPS Growth
- EXEL 237.58
- CHRW 64.94
- EPS
- EXEL 2.20
- CHRW 4.19
- Revenue
- EXEL $2,298,922,000.00
- CHRW $17,359,385,000.00
- Revenue This Year
- EXEL $9.37
- CHRW N/A
- Revenue Next Year
- EXEL $11.05
- CHRW $4.77
- P/E Ratio
- EXEL $18.12
- CHRW $22.30
- Revenue Growth
- EXEL 24.49
- CHRW N/A
- 52 Week Low
- EXEL $21.36
- CHRW $84.24
- 52 Week High
- EXEL $48.85
- CHRW $114.82
- Technical
- Relative Strength Index (RSI)
- EXEL 42.39
- CHRW 39.58
- Support Level
- EXEL $41.03
- CHRW $93.08
- Resistance Level
- EXEL $42.07
- CHRW $94.50
- Average True Range (ATR)
- EXEL 0.95
- CHRW 1.57
- MACD
- EXEL -0.42
- CHRW -0.46
- Stochastic Oscillator
- EXEL 12.85
- CHRW 5.41
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About CHRW C.H. Robinson Worldwide Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 61% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (27%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.